Protalix BioTherapeutics For Profit
Protalix is dedicated to bringing to market recombinant therapeutic proteins with clinically improved profiles, produced with its ProCellEx® plant cell-based expression system
Investors
Total Funding:
$10.8M
Headquarters:
Carmiel, HaZafon, Israel
Funding Status:
IPO
Employee Number:
501-1000
Estimated Revenue:
$10M to $50M
Last Funding Type:
Seed
Technology:
Drug development
Investors Number:
1
Founded Date:
1994-01-01
Industry:
PharmTech